Context Therapeutics director granted 45,000 stock options

Context Therapeutics Inc. director Andy Pasternak received a grant of stock options covering 45,000 shares of common stock.

Rhea-AI Filing Summary

Context Therapeutics Inc. director Andy Pasternak received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $0.576 per share and expire on June 23, 2036. Following this grant, he holds 45,000 options directly.

The option vests and becomes exercisable on the earlier of June 24, 2027, which is the one-year anniversary of the grant date, or the company’s 2027 annual meeting of stockholders, subject to his continued service with the company.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 1 txn

Insider Pasternak Andy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 45,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Key Figures

Option grant size: 45,000 options Exercise price: $0.576 per share Underlying shares: 45,000 shares +3 more

6 metrics

Option grant size 45,000 options Stock Option (right to buy) granted to director

Exercise price $0.576 per share Exercise price for underlying common stock

Underlying shares 45,000 shares Common stock underlying the option grant

Options after transaction 45,000 options Total derivative holdings following this grant

Vesting date trigger June 24, 2027 Earlier of this date or 2027 annual meeting

Expiration date June 23, 2036 Option expiration if unexercised

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.5760" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests and becomes exercisable on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders, subject to continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CNTX director Andy Pasternak report in this Form 4 filing?

Andy Pasternak reported receiving a grant of stock options for 45,000 shares of Context Therapeutics common stock. These options are compensation-related, not an open-market share purchase or sale, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of Andy Pasternak’s new CNTX stock options?

The granted stock options have an exercise price of $0.576 per share. This means Pasternak can buy Context Therapeutics common stock at $0.576 once the options vest and become exercisable, regardless of the market price at that time.

When do Andy Pasternak’s CNTX stock options vest and become exercisable?

The options vest on the earlier of June 24, 2027 or Context Therapeutics’ 2027 annual stockholder meeting. Vesting is contingent on Pasternak’s continued service with the company through that date, after which the options may be exercised.

How many CNTX options does Andy Pasternak hold after this transaction?

After this grant, Pasternak holds 45,000 stock options directly. All 45,000 options relate to Context Therapeutics common stock and were acquired in this single compensation-related grant reported in the Form 4 filing.

When do Andy Pasternak’s CNTX stock options expire if unexercised?

The options expire on June 23, 2036 if not exercised earlier. After this expiration date, Pasternak would no longer have the right to purchase Context Therapeutics common stock under this specific option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pasternak Andy

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915 UNIT #15

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.576	06/24/2026		A		45,000		(1)	06/23/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)